Scholarlink

<p>Immunosuppression of various origins is associated with an increased risk of infections and infection-triggered morbidity and mortality. Vaccination, therefore, plays a central role in the care of immunosuppressed individuals by protecting against vaccine-preventable diseases.</p><p>Based on the available evidence as well as immunological and theoretical considerations, an expert statement on vaccination in immunocompromised individuals was first formulated in 2016. These recommendations have herewith been comprehensively updated and expanded. The aim is to provide a practice‐oriented, indication‐ and therapy-specific guidance document for clinical care. A practical chart accompanying the present vaccination recommendation, which also functions as a decision tree for implementation, facilitates orientation within the document.</p><p>The document includes an introductory section outlining fundamental aspects of immunosuppression and addressing immunological and organizational issues relevant to vaccination planning, application, and control of vaccination responsiveness. In addition, current developments regarding relevant vaccines are reviewed.</p><p>Subsequently, a systematic overview of immunosuppressive agents commonly used across medical specialties is provided. These agents are categorized according to their degree of immunosuppression and the associated infection risks. Standardized vaccination schedules are provided and assigned to the respective drug classes to facilitate a structured approach in clinical practice. The decision on vaccination eligibility of these patients can only be made based on a comprehensive assessment of the underlying disease and the planned or ongoing immunosuppressive therapy.</p><p>Special clinical situations—including circumstances in which vaccination cannot be performed, as well as travel‐related vaccinations in the context of immunosuppression—are addressed in separate chapters. To ensure long‐term relevance, the document refers to continuously updated external sources throughout, which are compiled at the end.</p><p>This document acts as general recommendation without a claim of completeness. The specific procedure in clinical practice can be adapted to the clinical context, and the reader is referred to the respective professional societies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impfungen bei Immunsuppression, Immundefekten und immunmodulierenden Therapien: Empfehlungen – Update 2026

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月3日

查看全文
  • Ursula Wiedermann,
  • Angelika Wagner,
  • Alexander Bartuschka,
  • Anna Sophie Berghoff,
  • Alexandra Donschacher,
  • Alexander Eser,
  • Elisabeth Förster-Waldl,
  • Lisa Göschl,
  • Katharina Grabmeier-Pfistershammer,
  • Felix Keil,
  • Elisabeth König,
  • Sabine Koppelstätter,
  • Barbara Kornek,
  • Robert Krause,
  • Winfried F. Pickl,
  • Clemens Scheinecker,
  • Barbara Waas,
  • Günter Weiss,
  • Lukas Wisgrill,
  • Ursula Wiedermann,
  • Angelika Wagner,
  • Lisa Göschl,
  • Clemens Scheinecker,
  • Katharina Grabmeier-Pfistershammer,
  • Alexander Eser,
  • Barbara Kornek,
  • Anna Sophie Berghoff,
  • Alexandra Donschacher,
  • Felix Keil,
  • Elisabeth Förster-Waldl,
  • Lukas Wisgrill,
  • Winfried F. Pickl,
  • Alexander Bartuschka,
  • Barbara Waas,
  • Alexander Bartuschka,
  • Andrea Wessely,
  • Sabine Koppelstätter,
  • Angelika Wagner,
  • Ursula Wiedermann,
  • Christina Duftner,
  • Robert Krause,
  • Elisabeth König,
  • Günter Weiss,
  • Heinz Burgmann,
  • Barbara Tucek,
  • Daniela Philadelphy,
  • Marcus Köller,
  • Heidemarie Holzmann

摘要

Immunosuppression of various origins is associated with an increased risk of infections and infection-triggered morbidity and mortality. Vaccination, therefore, plays a central role in the care of immunosuppressed individuals by protecting against vaccine-preventable diseases.

Based on the available evidence as well as immunological and theoretical considerations, an expert statement on vaccination in immunocompromised individuals was first formulated in 2016. These recommendations have herewith been comprehensively updated and expanded. The aim is to provide a practice‐oriented, indication‐ and therapy-specific guidance document for clinical care. A practical chart accompanying the present vaccination recommendation, which also functions as a decision tree for implementation, facilitates orientation within the document.

The document includes an introductory section outlining fundamental aspects of immunosuppression and addressing immunological and organizational issues relevant to vaccination planning, application, and control of vaccination responsiveness. In addition, current developments regarding relevant vaccines are reviewed.

Subsequently, a systematic overview of immunosuppressive agents commonly used across medical specialties is provided. These agents are categorized according to their degree of immunosuppression and the associated infection risks. Standardized vaccination schedules are provided and assigned to the respective drug classes to facilitate a structured approach in clinical practice. The decision on vaccination eligibility of these patients can only be made based on a comprehensive assessment of the underlying disease and the planned or ongoing immunosuppressive therapy.

Special clinical situations—including circumstances in which vaccination cannot be performed, as well as travel‐related vaccinations in the context of immunosuppression—are addressed in separate chapters. To ensure long‐term relevance, the document refers to continuously updated external sources throughout, which are compiled at the end.

This document acts as general recommendation without a claim of completeness. The specific procedure in clinical practice can be adapted to the clinical context, and the reader is referred to the respective professional societies.